PET Imaging Study for Large B-Cell Lymphoma Patients Using 89Zr-CED88004S Before and After CAR T-Cell Therapy

1 1 1

What is this study about?

This clinical trial focuses on patients with large B-cell lymphoma, a type of cancer that affects the lymphatic system. The study involves a special imaging technique called PET imaging to observe the behavior of certain immune cells, known as CD8+ T-cells, before and after a treatment called CAR T-cell therapy. The treatment uses a tracer called ZED88082A/CED88004S, which is injected into the body to help visualize these immune cells during the imaging process.

The purpose of the study is to understand how CD8+ T-cells are distributed in the body and how they interact with the cancer both before and after the CAR T-cell therapy. This is done by using the PET imaging technique to capture images of the body and analyze the presence and activity of these immune cells. The study aims to see how the distribution of these cells might relate to the effectiveness of the CAR T-cell therapy in treating the lymphoma.

Participants in the study will receive the tracer injection and undergo PET imaging at different stages of their treatment. The study will monitor the uptake of the tracer in both normal tissues and tumor areas to gather information on how the immune cells are behaving. This information could help improve understanding of the treatment process and potentially lead to better outcomes for patients with large B-cell lymphoma.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying a diagnosis of large B-cell lymphoma and ensuring the ability to undergo CAR T-cell therapy.

A biopsy of the tumor lesion is performed if it can be safely obtained. This is necessary to measure disease according to the Lugano criteria.

2 pre-treatment imaging

Before starting CAR T-cell therapy, a PET scan is conducted using the tracer ZED88082A/CED88004S. This scan helps to visualize the distribution of CD8+ T-cells in the body.

The tracer is administered through an intravenous injection. The scan is performed two days after the injection to assess the uptake in normal tissues and tumor lesions.

3 CAR T-cell therapy

The patient receives CD19-directed CAR T-cell therapy. This therapy involves modifying the patient’s own T-cells to better target and attack cancer cells.

The therapy is administered according to the standard clinical care procedures.

4 post-treatment imaging

After the CAR T-cell therapy, another PET scan is conducted using the same tracer, ZED88082A/CED88004S. This helps to evaluate changes in the distribution of CD8+ T-cells post-therapy.

The scan is again performed two days after the tracer injection to measure the uptake in the body and tumor lesions.

5 safety and response assessment

Throughout the study, safety assessments are conducted to monitor any adverse effects related to the tracer and the CAR T-cell therapy.

The response to the therapy is evaluated by correlating the imaging results with the expression of CD8 in tumor biopsies and the persistence of CAR T-cells in the blood.

Who Can Join the Study?

Patients must have a confirmed diagnosis of Large B-cell lymphoma (LBCL), which is a type of cancer that affects the lymphatic system.
Female patients who can have children and male patients with partners who can have children must agree to use a very reliable form of birth control to prevent pregnancy during the study.
Patients must meet the requirements for anti-CD19 CAR T-cell therapy, which is a treatment that uses the patient’s own immune cells to fight cancer.
Patients must have a tumor lesion that can be safely biopsied, meaning a small sample of the tumor can be taken for examination.
Patients must have a measurable disease, which means the cancer can be measured and tracked over time, as defined by the Lugano criteria, a set of guidelines for evaluating lymphoma.
Patients must sign an informed consent, which is a document that explains the study and confirms their willingness to participate.
Patients must be 18 years or older at the time they sign the informed consent.
Patients must have a life expectancy of at least 12 weeks, meaning they are expected to live for at least 12 more weeks.
Patients must have an ECOG performance status of 0-1, which is a scale used to assess how well a patient can perform daily activities. A score of 0-1 indicates that the patient is fully active or has some symptoms but can still carry out light work.
Patients must be able to comply with the protocol, meaning they can follow the study’s rules and procedures.

Who Cannot Join the Study?

Patients who do not have Large B-cell lymphoma cannot participate. This is a type of cancer that affects certain white blood cells.
Patients who are not within the specified age range cannot participate. The age range includes adults and older adults.
Patients who are not willing or able to undergo the specific imaging tests required by the study cannot participate. These tests help to see how certain cells are distributed in the body.
Patients who are part of a vulnerable population, such as those who cannot make decisions for themselves, cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Unxbxzlwxeha Mnawvvq Ckgwfjf Gyzsgiuzd	Groningen	The Netherlands

Trial status

Country	Status	Recruitment Start
The Netherlands	Not recruiting	01.03.2021

Trial locations

Investigated drugs:

89ZR-CED88004S

ZED88082A/CED88004S is an imaging agent used in this study to visualize and track CD8+ T-cells in patients with large B-cell lymphoma. This agent is used in PET imaging to help researchers see how these immune cells are distributed in the body before and after the patient receives CAR T-cell therapy. The imaging helps to understand how well the therapy is working by showing where the T-cells are located and how they are interacting with the tumor.

CD19-directed CAR T-cell therapy is a type of treatment that uses the patient’s own immune cells, which are modified in the lab to better recognize and attack cancer cells. In this trial, the therapy is specifically designed to target cells that have the CD19 protein on their surface, which is common in certain types of lymphoma. The goal of this therapy is to help the immune system find and destroy cancer cells more effectively.

Investigated diseases:

B-cell lymphoma

Large B-cell lymphoma – This is a type of non-Hodgkin lymphoma that originates in the lymphatic system, specifically affecting B-cells, which are a type of white blood cell. It is characterized by the rapid growth of large, abnormal B-cells in the lymph nodes, spleen, or other organs. As the disease progresses, it can spread to other parts of the body, including the bone marrow and central nervous system. Symptoms may include swollen lymph nodes, fever, night sweats, and unexplained weight loss. The disease can vary in its rate of progression, with some cases advancing quickly while others develop more slowly. Understanding the distribution and behavior of these cells is crucial for developing effective treatments.

Trial ID:

2025-520560-18-00

Trial Phase:

Therapeutic use (Phase IV)

Other Trials to Consider

#1 Clinical Trials Search in Europe

PET Imaging Study for Large B-Cell Lymphoma Patients Using 89Zr-CED88004S Before and After CAR T-Cell Therapy

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?